Clinical Trials

NCT IdNCT04833517
TitleProspective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)
ConditionProstate Cancer Metastatic
StudyTypeObservational
OrganizationUniversität des Saarlandes
Sponsor/CollaboratorsUniversität des Saarlandes
StatusRecruiting
GenderMale
AgeGroupAdult
Older Adult
Location (with distance)
  • Dept. of Nuclear Medicine, Saarland University, Homburg, 66421 , Germany
DescriptionThis prospective registry aims to assess outcome and toxicity of targeted radionuclide therapies in patients with advanced prostate cancer in clinical routine. While the major investigated treatment modality is prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, also other radionuclide therapies such as Ra223 and liver-directed radioembolization are included. The investigators believe that prospectively assessed long-term outcome data on implementation of radionuclide therapy, especially in the palliative setting of advanced mCRPC, help to better define the real benefits and risks of the respective treatment modalities for patients regarding survival and quality-of-life.